Inhaled bronchodilators for cystic fibrosis

Both short and long-acting beta-2 agonists may be beneficial both in the short and long term in individuals with cystic fibrosis who have bronchodilator responsiveness or bronchial hyperresponsiveness.

A Cochrane review [withdrawn from publication] included 18 studies with a total of 369 subjects. A meta-analysis was not possible. There were varied conclusions from the different trials reflecting their heterogeneity. Compared to placebo, short-acting beta-2 agonists increased FEV₁ in the short term in three out of five trials, and in the long-term increased peak expiratory flow rate in individuals who had been shown to have bronchial hyperreactivity or bronchodilator responsiveness or both. Compared to placebo, long-acting beta-2 agonists increased FEV₁ and forced expiratory flow between 25% and 75% of expiratory flow (FEF 25–75%) in the short term in participants known to have bronchodilator responsiveness, but produced inconsistent results in long-term trials. Short-acting anticholinergics had no consistent effect on lung function tests in either the short or the long term.

Comment: The quality of evidence is downgraded by imprecise results (limited study size for each comparison) and by inconsistency (variability in results across studies).

Ədəbiyyat

1. Halfhide C, Evans HJ, Couriel J. WITHDRAWN: Inhaled bronchodilators for cystic fibrosis. Cochrane Database Syst Rev 2016;(2):CD003428. 4 April 2011]"?>.